Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Robert Nelsen Insider Profile
25 Followers
Robert Nelsen, Director at Juno Therapeutics, holds 0.00 shares in Juno Therapeutics (Ticker: JUNO), holds ― shares in Sienna Biopharmaceuticals (Ticker: SNNAQ), holds 15.47M shares in Prime Medicine, Inc. (Ticker: PRME).
Profitable Transactions
4 out of 11 Profitable Transactions
Average Return
+26.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Robert Nelsen holds in companies
Most Profitable Insider Trade
Stock:
Karuna Therapeutics
(KRTX)
(KRTX)
Rating:Informative Buy
Date:Jul 02, 2019 - Jul 02, 2020
Return:+405.70%
The most profitable trade made by Robert Nelsen
Robert Nelsen's Trading History
Juno Therapeutics
Mar 07, 2018
―
Uninformative Sell
922.76M
$0.00
Sienna Biopharmaceuticals
―
Director, Ten Percent Owner
―
―
Denali Therapeutics
Jun 04, 2021
Director
Uninformative Buy
―
$165.94M
Unity Biotechnology
May 07, 2018
Director
Uninformative Buy
―
$16.08M
Karuna Therapeutics
Apr 15, 2021
―
Uninformative Buy
―
$482.11M
Vir Biotechnology
May 24, 2023
Director, Ten Percent Owner
Uninformative Buy
―
$138.24M
Beam Therapeutics
Apr 02, 2021
Director, Ten Percent Owner
Uninformative Buy
―
$80.54M
Sana Biotechnology
Feb 12, 2024
Director, Ten Percent Owner
Informative Buy
10.00M
$227.61M
Lyell Immunopharma
Jun 23, 2021
Director, Ten Percent Owner
Uninformative Buy
―
$92.49M
Prime Medicine, Inc.
Feb 20, 2024
Director, Ten Percent Owner
Informative Buy
20.00M
$83.55M
Agios Pharma
Mar 07, 2017
Director
Informative Sell
2.06M
$55.74M
SAGE Therapeutics
Nov 12, 2015
Director
Uninformative Buy
―
$16.33M
Bellerophon
Feb 23, 2015
Director, Ten Percent Owner
Uninformative Sell
―
$54.08K
Kythera
Mar 26, 2015
―
Informative Buy
108.26K
$771.92K
Alnylam Pharma
―
Ten Percent Owner
―
$33.65M
Fate Therapeutics
Oct 04, 2013
Director, Ten Percent Owner
Uninformative Buy
770.68K
$10.44M
Neurogesx
Jul 26, 2011
―
Informative Buy
2.88M
$20.94K
Cyclacel Pharmaceuticals
―
Director, Ten Percent Owner
―
$0.00
List of latest transactions for each holding click on a transaction to see Robert Nelsen's performance on stock
You May Also Like
Robert Nelsen insider profile FAQ
What is the percentage of profitable transactions made by Robert Nelsen?
The percentage of profitable transactions made by Robert Nelsen is 36%.
What is the average return per transaction made by Robert Nelsen?
The average return per transaction made by Robert Nelsen is 26.80%.
What stocks does Robert Nelsen hold?
Robert Nelsen holds: JUNO, SNNAQ, DNLI, UBX, KRTX, VIR, BEAM, SANA, LYEL, PRME, AGIO, SAGE, BLPH, KYTH, ALNY, FATE, NGSX, CYCC stocks.
What was Robert Nelsen’s latest transaction?
Robert Nelsen latest transaction was an Uninformative Sell of $922.76M.
What was Robert Nelsen's most profitable transaction?
Robert Nelsen’s most profitable transaction was an Informative Buy of KRTX stock on July 2, 2019. The return on the trade was 405.70%.
What is Robert Nelsen's role in Juno Therapeutics?
Robert Nelsen's role in Juno Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.